AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00172809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfa-2a
Description: Interferon alfa-2a 3 MU tiw for 24 weeks
Study NCT00289133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Gamma Vacuum Foil polyethylene tibial insert
Study NCT00289133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: cross-linked polyethylene tibial insert
Study NCT02644642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disconnection technique
Description: Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
Study NCT00622817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylometazoline HCL 0.05%
Description: Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
Study NCT00622817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1mg
Description: Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
Study NCT05988008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.
Study NCT05988008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT02139995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBC transfusion based on different protocols
Description: transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
Study NCT02139995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion based on different protocols
Description: transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
Study NCT00000255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide
Study NCT00000255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Study NCT04960631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Double site CT guided needle biopsy
Description: Double site CT guided needle biopsy
Study NCT03109249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1613
Description: Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
Study NCT03109249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference1613
Description: Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
Study NCT03033485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-P3BZA
Description: 18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
Study NCT04253223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: REMD-477 will be administered as a subcutaneous injection for three weekly doses
Study NCT01954992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide
Description: Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
Study NCT01954992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
Study NCT00760123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Physical Therapy and Educational strategy
Description: Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy
Study NCT00760123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Physical Therapy and Educational strategy
Description: Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy
Study NCT02208479 — intervention group
Intervention type: OTHER
Intervention: Non invasive ultrasound measurement of the diaphragm thickness during breathing
Study NCT03824288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound
Description: The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
Study NCT03824288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The landmark technique
Description: A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
Study NCT03475368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
Study NCT04288219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Positive Pressure Ventilation
Description: Continuous positive airway pressure delivered by face mask at 10cmH2O
Study NCT04288219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine 30mg, Pharmacotherapy
Study NCT04288219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 30mg, Pharmacotherapy
Study NCT04288219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplemental oxygen
Description: supplemental oxygen
Study NCT01366664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence 2
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
Study NCT01366664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence 1
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
Study NCT03400124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISBCS
Description: The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
Study NCT03400124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSBCS
Description: The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
Study NCT03324035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
Study NCT03324035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
Study NCT03324035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Administer to both arms on as needed scheme, to a maximum of 150mg/day.
Study NCT03324035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Administer to both arms on as needed scheme, to a maximum of 150mg/day.
Study NCT00771446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD plus standard of care treatment
Description: ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
Study NCT00771446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
Study NCT00771446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
Study NCT04594759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Participants will be getting isotretinoin (1-1.5 mg/kg/week)
Study NCT03830866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion every 4 weeks
Study NCT02753036 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
Study NCT02807064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacteria
Description: 0.5 ml per os all days for 2 months
Study NCT02807064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0,5 ml per os all days for 2 months
Study NCT01142609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eGet
Description: eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mL
Description: Levobupivacaine 0.25% 5 mL in adductor canal nerve block
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mL
Description: Levobupivacaine 0.25% 10 mL in adductor canal nerve block
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 15 mL
Description: Levobupivacaine 0.25% 15 mL in adductor canal nerve block
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 20 mL
Description: Levobupivacaine 0.25% 20 mL in adductor canal nerve block
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 25 mL
Description: Levobupivacaine 0.25% 25 mL in adductor canal nerve block
Study NCT02557386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 30 mL
Description: Levobupivacaine 0.25% 30 mL in adductor canal nerve block
Study NCT00663728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg Vardenafil taken orally 1 hour prior to sexual intercourse
Study NCT00663728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03830866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Study NCT03830866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Study NCT02415439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15
Study NCT00648024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agrylin® Capsules 1 mg
Description: 1mg, single dose fasting
Study NCT03830866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Study NCT03830866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Study NCT03830866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care
Study NCT03830866 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care
Study NCT00381173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Description: Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
Study NCT03559348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: TS-1, Leucovorin and Gemcitabine
Description: Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
Study NCT03010618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hall technique stainless steel crowns
Description: Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
Study NCT03220425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Study NCT03220425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Study NCT01094249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium ER/paliperidone ER
Description: Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
Study NCT01677013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMMCT
Description: Bone marrow mononuclear cell transplantation via selective catheterization
Study NCT00109759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RagweedMATAMPL
Study NCT00109759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01700478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol + vasopressin
Description: 400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
Study NCT01700478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin was used in all patients during surgery.
Study NCT00207194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Telephone Program
Description: The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
Study NCT00207194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Behavior Education
Description: Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
Study NCT00207194 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Behavior Education
Description: Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
Study NCT00822393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 4 x 0.8 mg/kg/d Intravenous Day -4 and -3
Study NCT00822393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 10 g/m2/d Intravenous Day -4, -3, -2
Study NCT01931527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Study NCT03870113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinated group
Description: Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
Study NCT03606720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
Study NCT03606720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
Study NCT03606720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic stabilization exercises
Description: special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
Study NCT03606720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic stabilization exercises
Description: special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
Study NCT00522444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: 6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
Study NCT00522444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline
Description: standard of care
Study NCT01100879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Study NCT03634345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Day 1: PF-04965842 administered
Description: Period 1: Single administration of 100 mg PF 04965842.
Study NCT03634345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Cohort 1: Fluvoxamine & PF-04965842
Description: Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
Study NCT03522337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual pedagogy (social stories)
Description: Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)